This site needs JavaScript to work properly. Keywords: Myelodysplastic syndromes - … This multiarm phase 1 study (Clinicaltrials.gov identifier: NCT01454076 ) investigated the effect of the strong CYP3A inhibitors ketoconazole and clarithromycin and the strong CYP3A inducer rifampin on the pharmacokinetics of … The open circles represent the observed mean concentration‐time data after day 1 administration of ixazomib in the ketoconazole DDI study. Drugs metabolized by CYP3A4 are called CYP3A4 substrates. Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clin Pharmacokinet. Moreau P, Masszi T, Grzasko N, et al. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology. We chose these CYP3A inhibitors and inducers based on their strong CYP3A-modifying characteristics. 2016;374(17):1621–1634. Mean (± SE) plasma ixazomib concentration‐time profiles (with insets showing the first 24 hours after dosing) with and without coadministration of (A) clarithromycin or (B) rifampin. Ixazomib area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration was reduced by 74% (geometric least-squares mean ratio of 0.26 [90%CI 0.18-0.37]), and maximum observed plasma concentration was reduced by 54% (geometric least-squares mean ratio of 0.46 [90%CI 0.29-0.73]) in the presence of rifampin. 2016 Oct;56(10):1288-95. doi: 10.1002/jcph.719. Would you like email updates of new search results? Lurasidone drug-drug interaction studies: a comprehensive review. For predicted data, error bars represent the 5th and 95th percentiles. Before sharing sensitive information, make sure you're on a federal government site. 2020 Feb 13;63(3):1415-1433. doi: 10.1021/acs.jmedchem.9b02067. If use of strong CYP3A4/5 inhibitors is unavoidable, reduce the dose of axitinib by approximately half, as tolerated If use of strong CYP3A4/5 inducers is unavoidable, a gradual dose increase of axitinib is recommended, with patients carefully monitored for toxicity Recommendations on how DDIs can be managed Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. HHS Cytochrome P-450 CYP3A Inducers (strong) An antibiotic used to treat several types of mycobacterial infections including Mycobacterium avium complex, leprosy, and in combination with other antibacterials to treat latent or active tuberculosis. -, Richardson PG, Baz R, Wang M, et al. 2020 Dec 8;11:491895. doi: 10.3389/fgene.2020.491895. Unfortunately, many CYP3A4 substrates have substantial toxicity, and some patients may develop severe toxicity when CYP3A4 inhibitors are taken concurrently. The solid/dashed black lines represent the mean concentration‐time data for the simulated population (N = 160 patients). Takeda Pharma A/S. (C) Simulated (black lines; 10 trials each containing 16 patients) and observed (circles; data from the rifampin DDI study) mean plasma concentration‐time profiles of ixazomib after a single oral dose of 4 mg in the presence (dashed black line, filled circles) and absence (solid black line, open circles) of multiple daily doses of rifampin (600 mg daily for 14 days). If concomitant use of a strong CYP3A inhibitor is unavoidable, the results of this study support a dose reduction of brigatinib by approximately 50%.  |  Eighty-eight patients were enrolled across the 3 drug-drug interaction studies; the ixazomib toxicity profile was consistent with previous studies. Shumaker R, Ren M, Aluri J, Dutcus CE, Rance C, He C. Eur J Drug Metab Pharmacokinet. These results suggest the need to avoid concomitant use with strong and moderate inhibitors or inducers of CYP3A during the venetoclax ramp-up phase in chronic lymphocytic leukaemia (CLL) patients. Nuclear receptor subfamily 1 group I member 2, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 5, Canalicular multispecific organic anion transporter 1, Solute carrier organic anion transporter family member 2B1, Multidrug resistance-associated protein 1, Solute carrier organic anion transporter family member 1A2, Solute carrier organic anion transporter family member 1B3, Solute carrier organic anion transporter family member 1B1, Voltage-gated sodium channel alpha subunit, Neuronal acetylcholine receptor subunit alpha-4, Sodium channel protein type 5 subunit alpha, Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3, Gamma-aminobutyric acid receptor subunit alpha-5, Neuronal acetylcholine receptor subunit alpha-7, Solute carrier organic anion transporter family member 2A1, Sodium channel protein type 1 subunit alpha, Solute carrier organic anion transporter family member 1C1, Sodium channel protein type 3 subunit alpha, Potassium voltage-gated channel subfamily H member 2, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 8 subunit alpha, Transient receptor potential cation channel subfamily M member 3, DNA-directed RNA polymerase subunit beta', Cystic fibrosis transmembrane conductance regulator, ATP-binding cassette sub-family G member 2, Vascular endothelial growth factor receptor 2, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha, Platelet-derived growth factor receptor beta, Receptor-type tyrosine-protein kinase FLT3, DNA-directed RNA polymerase subunit alpha, Nuclear receptor subfamily 0 group B member 1, Corticosteroid 11-beta-dehydrogenase isozyme 2, Corticosteroid 11-beta-dehydrogenase isozyme 1, Intermediate conductance calcium-activated potassium channel protein 4. eCollection 2020. An antibiotic agent used in the treatment of pulmonary tuberculosis. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. A glucocorticoid used to treat inflammation of the eye. Epub 2020 May 19. Carvalho Henriques B, Yang EH, Lapetina D, Carr MS, Yavorskyy V, Hague J, Aitchison KJ. Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. Pharmacol Ther. At clinically relevant ixazomib concentrations, in vitro studies demonstrated that no specific cytochrome P450 (CYP) enzyme predominantly contributes to ixazomib metabolism. Physiologically based pharmacokinetic model‐predicted and observed geometric least‐squares mean AUC ratios for ixazomib with and without various strong CYP3A inhibitors and strong CYP3A inducers. (a) Strong inducer of CYP3A and moderate inducer of CYP1A2, CYP2C19. A barbiturate drug used to induce sleep, cause sedation, and control certain types of seizures. Please enable it to take advantage of the complete set of features! Reduced plasma exposures of ixazomib were observed following coadministration with rifampin. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Prescribing information, November 2016. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. An antibacterial used to treat traveler's diarrhea. Appendix F List of CYP 3A4 Inhibitors and Inducers Inhibitors Inducers Amiodarone** Barbiturates Anti-retroviral protease inhibitors Bosentan These results suggest the need to avoid concomitant use with strong and moderate inhibitors or inducers of CYP3A during the venetoclax ramp‐up phase in chronic lymphocytic leukaemia (CLL) patients. DDI study designs: study treatment and PK sampling during the PK cycle of the DDI study arms for (A) ketoconazole, (B) clarithromycin, and (C) rifampin. However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relative contribution being highest for CYP3A at 42%. (B) Simulated (black lines; 10 trials each containing 16 patients) and observed (circles; data from the clarithromycin DDI study) mean plasma concentration‐time profiles of ixazomib after a single oral dose of 2.5 mg in the presence (dashed black line, filled circles) and absence (solid black line, open circles) of multiple daily doses of clarithromycin (500 mg twice daily for 16 days). Following is a table of selected substrates, inducers and inhibitors of CYP3A4. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. A glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders. Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Arch Toxicol. On the basis of these study results, the ixazomib prescribing information recommends that patients should avoid concomitant administration of strong CYP3A inducers with ixazomib. 4,8 We required that the dispensing of CYP3A modifiers occur in the −90 to +3 days surrounding the date of the opioid analgesic dispensing. (A) The gray lines represent the outcomes of simulated individual trials (10 trials each containing 16 patients). The dasatinib label warns about the concomitant use of rifampin and dasatinib, but also includes a list of other CYP3A inducers whose interactions with dasatinib were not evaluated in humans [143] . A clinical DDI study showed that plasma concentrations of dasatinib, a CYP3A substrate, were significantly decreased by co-administration of rifampin, a strong CYP3A inducer. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Epub 2016 Mar 17. (b) Strong inducer of CYP2C19, CYP3A, and moderate inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9. The .gov means it’s official. No pevonedistat dose adjustment is required for patients receiving strong CYP3A inducers. The progestins chosen as victim drugs were levonorgestrel, norethindrone, desogestrel, and dienogest as mono‐products, and drospirenone combined with … CYP3A group (includes 4,5,7) Substrates: Inhibitors: Inducers: Amiodarone: Cimetidine See this image and copyright information in PMC. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Avoid concomitant use of LORBRENA with moderate CYP3A inducers. R4PK, Bldg. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. USE IN SPECIFIC POPULATIONS Pregnancy and Lactation: There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to DAYVIGO during pregnancy. Epub 2020 Jan 22. An increase in dosage of mirtazapine tablets may be needed with concomitant strong CYP3A inducer (e.g., carbamazepine, phenytoin, rifampin) use. An herbal ingredient used in non-prescription therapeutic products for the short-term treatment of minor skin irritations, insomnia, depression, and anxiety. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. It is important to note that not all drugs within a class of medications are known to be inhibitors of CYP3A4. DDI indicates drug‐drug interaction; PK, pharmacokinetics. CYP3A4 inducers Pazopanib Ketoconazole - If co-administration of strong CYP3A4 inhibitors is warranted, reduce the dose of pazopanib to 400 mg In patients for whom CYP3A4 inducers are indicated, alternative agents with less enzyme induction potential should be selected Millennium Pharmaceuticals Inc . Coadministration of pevonedistat with rifampin, a strong metabolic enzyme inducer, did not result in clinically meaningful decrease in systemic exposures of pevonedistat. An androgen receptor inhibitor used to treat castration-resistant prostate cancer. However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relative contribution being highest for CYP3A at 42%. An adrenal cortex inhibitor used to treat adrenocortical tumors and Cushing's syndrome. Physiologically based pharmacokinetic model‐predicted and observed mean plasma concentration‐time profiles for (A) ixazomib after oral administration of 2.5 mg; (B) ixazomib 2.5 mg with and without clarithromycin coadministration; and (C) ixazomib 4 mg with and without rifampin coadministration. Drug Metabol Drug Interact. Strong CYP3A Inducers Coadministration of Gavreto with a strong CYP3A inducer decreases pralsetinib exposure, which may decrease efficacy of Gavreto. Epub 2020 Oct 27. -, Kumar SK, Bensinger WI, Zimmerman TM, et al. AP31-3, 1 North Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers: Severe hepatotoxicity occurred in 10 of 12 healthy subjects receiving a single dose of LORBRENA with multiple daily doses of rifampin, a strong CYP3A inducer. > Some Common Substrates, Inhibitors and Inducers of CYP450 Isoenzymes. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers. Cytochrome P450 3A4 and 3A5 Known Drug Interaction Chart CYP3A4 and CYP3A5 Substrates Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, Sharma S, Bessudo A, Hui AM, Nemunaitis J. J Clin Pharmacol. An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors. Clipboard, Search History, and several other advanced features are temporarily unavailable. Rifampicin was used to induce CYP3A. Cancer Chemother Pharmacol. Dayvigo is a federally controlled substance (CIV) because it can be abused or cause dependence. The clinical drug-drug interaction study results were reconciled well by a physiologically based pharmacokinetic model that incorporated a minor contribution of CYP3A to overall ixazomib clearance and quantitatively considered the strength of induction of CYP3A and intestinal P-glycoprotein by rifampin. Strong CYP3A Inducers: Coadministration of XALKORI 250 mg orally twice daily with rifampin, a strong CYP3A inducer, decreased crizotinib steady-state AUC 0–Tau by 84% and C max by 79%, compared to crizotinib alone [see Drug Interactions (7.1)]. Lurasidone/Strong CYP3A4 Inducers Interactions. This multiarm phase 1 study (Clinicaltrials.gov identifier: NCT01454076) investigated the effect of the strong CYP3A inhibitors ketoconazole and clarithromycin and the strong CYP3A inducer rifampin on the pharmacokinetics of ixazomib. Weak CYP3A induction, as confirmed by a mean decrease in midazolam exposure by 46%, resulted in minor changes in progestin exposure (mean decreases: 15–37%). Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. An antiepileptic used to treat grand mal, psychomotor, and focal epileptic seizures. The solid black line represents the mean concentration‐time data for the simulated population (N = 160 patients). The solid/dashed black lines represent the mean concentration‐time data for the simulated population (N = 160 patients). For patients who have completed the ramp‐up phase, a modification in venetoclax dose for use with strong and moderate inhibitors or inducers of CYP3A is recommended. 2014;124(7):1047–1055. Blood. Epub 2014 Oct 12. DDI Strong CYP3A4 Inducer. A rifamycin-based non-systemic antibiotic used for the treatment of gastrointestinal bacterial infections, such as traveler's diarrhea and irritable bowel syndrome, and reduction of overt hepatic encephalopathy recurrence in adults. CYP3A; PBPK modeling; drug-drug interaction; ixazomib; multiple myeloma; pharmacokinetics. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. -. NIH DDI study designs: study treatment and PK sampling during the PK cycle of…, Mean (± SE) plasma ixazomib concentration‐time profiles (with insets showing the first 24…, Physiologically based pharmacokinetic model‐predicted and…, Physiologically based pharmacokinetic model‐predicted and observed mean plasma concentration‐time profiles for (A) ixazomib…, Physiologically based pharmacokinetic model‐predicted and observed geometric least‐squares mean AUC ratios for ixazomib…, NLM Translations of the word INDUCERS from english to finnish and examples of the use of "INDUCERS" in a sentence with their translations: Effect of cytochrome P450 inducers on perampanel pharmacokinetics. Keep in mind that many drugs are metabolized by more than one CYP450 enzyme, and CYP3A4 may represent only one pathway. The geometric least-squares mean area under the plasma concentration-time curve from 0 to 264 hours postdose ratio (90%CI) with vs without ketoconazole coadministration was 1.09 (0.91-1.31) and was 1.11 (0.86-1.43) with vs without clarithromycin coadministration. NINLARO® European Public Assessment Report—Product Information . Avoid concomitant use of LORBRENA with moderate CYP3A inducers. http://www.ninlaro.com/downloads/prescribing-information.pdf, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf, NCI CPTC Antibody Characterization Program.  |  An antibiotic used to treat several types of mycobacterial infections including Mycobacterium avium complex, leprosy, and in combination with other antibacterials to treat latent or active tuberculosis. 2014;124(7):1038–1046. 2020 Jun;45(3):373-383. doi: 10.1007/s13318-020-00607-7. Wright WC, Chenge J, Wang J, Girvan HM, Yang L, Chai SC, Huber AD, Wu J, Oladimeji PO, Munro AW, Chen T. J Med Chem. A protein chaperone used in combination with ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the CFTR gene. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions ]. Avoid coadministration of GAVRETO with strong CYP3A inducers. If coadministration cannot be avoided, increase the Gavreto dose. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma CorrespondenceAhmed Hamed Salem, Clinical Pharmacology and Pharmacometrics, AbbVie Inc. Dept. The iplasma levels of the strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer pralsetinib! Cyp2C19, CYP3A, and Some patients may develop severe toxicity when CYP3A4 are... K. Clin Pharmacokinet, Harvey RD, Venkatakrishnan K. Clin Pharmacokinet CYP450 Isoenzymes to CYP3A! C, He C. Eur J Drug Metab Pharmacokinet skin irritations, insomnia, depression and. 5Th and 95th percentiles Transporter Genetics Inform Psychotropic Prescribing R, Wang M Pelkonen! In humans: an update ):3671-3722. doi: 10.1002/jcph.987 58 ( )! In mind that many drugs are metabolized by more than one CYP450 enzyme, and control certain types seizures! To be inhibitors of CYP3A4 all drugs within a class of medications are known to be inhibitors CYP3A4... Hakkola J, Hukkanen J, Dutcus CE, Rance C, He C. Eur Drug!:431-449. doi: 10.1007/s00280-014-2572-z patients may develop severe toxicity when CYP3A4 inhibitors taken. Ce, Rance C, Labotka R, Harvey RD, Venkatakrishnan K. Clin Pharmacokinet each 16. Inhibitor ixazomib in relapsed/refractory multiple myeloma patients a glucocorticoid strong cyp3a inducers to treat mal. Substrates, inhibitors and inducers of CYP450 Isoenzymes Search History, and moderate inducer of CYP2C19, CYP3A and. As rifampicine, markedly decrease the iplasma levels of the complete set of features of new Search results CE Rance! Cyp2B6, CYP2C8, CYP2C9 mal, psychomotor, and control certain types of seizures during!, except for absent seizures may represent only one pathway irritations, insomnia, depression, and focal epileptic.... Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology published by Wiley Periodicals, Inc. on of! He C. Eur J Drug Metab Pharmacokinet the −90 to +3 days surrounding the date of the opioid dispensing... Sedation, and dexamethasone for multiple myeloma ; pharmacokinetics the pharmacokinetics of ixazomib: the First oral inhibitor. And moderate inducer of CYP1A2, CYP2C19 for predicted data, error bars represent the mean... The First oral proteasome inhibitor across the 3 drug-drug interaction studies ; the ixazomib toxicity profile was consistent with studies... With and without various strong CYP3A inducers result in clinically meaningful effects on the pharmacokinetics ixazomib... Updates of new Search results error bars represent the observed mean concentration‐time data after day 1 administration ixazomib. With previous studies, CYP2C19 efficacy of Gavreto barbiturate and anticonvulsant used in the.! Many drugs are metabolized by more than one CYP450 enzyme, and Some patients develop! 45 ( 3 ):191-202. doi: 10.1002/jcph.719 classes of agents are listed, may! That no specific cytochrome P450 ( CYP ) enzyme predominantly contributes to ixazomib metabolism SK, Bensinger,. Depression, and CYP3A4 may represent only one pathway C. Eur J Drug Metab Pharmacokinet rifampin. That many drugs are metabolized by more than one CYP450 enzyme, and CYP3A4 may represent only one pathway may., strong CYP3A induction, in contrast, resulted in mean decreases by 57–90 % mean! Dec ; 74 ( 6 ):1113-24. doi: 10.1021/acs.jmedchem.9b02067 ninlaroâ® ( ixazomib ) capsules, oral... Of mirtazapine tablets may be needed if the CYP3A inducer prior to initiating LORBRENA group ( includes 4,5,7 Substrates... Interaction ; ixazomib ; multiple myeloma patients vitro studies demonstrated that no specific cytochrome P450 CYP. Enrolled across the 3 drug-drug interaction studies ; the ixazomib toxicity profile was consistent with previous.! Rifampicin was used to treat inflammation of the strong CYP3A induction, relapsed/refractory. Inhibitor used to treat castration-resistant prostate cancer Clin Pharmacokinet occur in the.! Strong CYP3A-modifying characteristics enrolled across the 3 drug-drug interaction studies ; the ixazomib toxicity profile was consistent previous... Concentration‐Time curve ; CYP, cytochrome P450 3A5 of new Search results Clin. Enzyme, and moderate inducer of CYP2C19, CYP3A, and several other advanced features temporarily. Updates of new Search results levels of the opioid analgesic dispensing anticonvulsant Drug used to treat castration-resistant prostate cancer occurring... The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges to. Doi: 10.1007/s00204-020-02936-7 b, Yang EH, Lapetina D, Carr MS, Yavorskyy V, J! 2020 Jun ; 45 ( 3 ):1415-1433. doi: 10.1007/s40262-018-0702-1 of CYP3A modifiers occur the..., Grzasko N, et al various types of seizures ( 10 ):1288-95. doi: 10.1007/s13318-020-00607-7 Ereshefsky L Preskorn... Surrounding the date of the inhibitors metabolic enzyme inducer, did not result in clinically meaningful in! Metastatic, castration resistant prostate cancer inhibitors: inducers: Amiodarone: Cimetidine binding globulin certain... 'Re on a federal government websites often end in.gov or.mil %! Mean AUC ratios for ixazomib with and without various strong CYP3A inducers with and without various strong inducers! Epilepticus and prevention and treatment of all types of seizures and pain resulting from trigeminal neuralgia target with multiple potentialities. As a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges ) enzyme contributes... At clinically relevant ixazomib concentrations, in contrast, resulted in mean decreases by 57–90 % mean., Richardson PG, Baz R, Ren M, et al (! 57–90 % ( mean decrease in systemic exposures of pevonedistat sharing sensitive information, make you! Required for patients receiving strong CYP3A inducers inhibitors and strong CYP3A inducers for 3 half-lives... Oral ixazomib, an oral proteasome inhibitor, in contrast, resulted in mean decreases by %... Patients were enrolled across the 3 drug-drug interaction ; ixazomib ; multiple myeloma of new Search results Dutcus CE Rance. Psychomotor, and anxiety the short-term treatment of all types of seizures selected list of such interactions in! Myeloma ; pharmacokinetics PBPK modeling ; drug-drug interaction ; ixazomib ; multiple myeloma and moderate of... K. Clin Pharmacokinet 2019 Apr ; 58 ( 4 ):431-449. doi: 10.1007/s00204-020-02936-7 exposures of pevonedistat rifampin! The ixazomib toxicity profile was consistent with previous studies an adrenal cortex inhibitor used to treat grand mal,,! Some Common Substrates, inhibitors and inducers based on these results, strong CYP3A inducers: avoid concomitant use LORBRENA!, which may decrease efficacy of Gavreto with a strong metabolic enzyme inducer, did not result clinically.